DarioHealth (NASDAQ: DRIO), a leader in the global digital therapeutics (“DTx”) market, has inked two additional contracts to provide its highly personalized digital therapeutic services; the contracts will be in effect beginning in 2022. Dario is now providing services to 49 clients multi chronic condition platform solutions, with demand continuing to grow. Dario offers its next-generation digital programs to support employers in their efforts to support their employees and address high-cost, high-priority chronic conditions, including diabetes, prediabetes, hypertension, weight management, musculoskeletal and behavioral health. The company also announced that it had issued an inducement grant of stock options to Jerrod Helms, its newly appointed Chief Commercial Officer. According to the company, the stock options were granted as an inducement material to Helms becoming an employee of the company and were in accordance with Nasdaq rules and regulations. “Dario is continuing to realize the robust demand for its solutions as opportunities developed over the last year convert into customers,” said DarioHealth president and general manager, North America, Rick Anderson in the press release. “These new contracts add to our growing list of customers and helps position Dario for a successful first quarter of 2022 with a significant increase in potential members.
To view the full press release, visit https://ibn.fm/kTrtq
About DarioHealth Corp.
DarioHealth is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. DarioHealth offers one of the most comprehensive digital therapeutics solutions on the market, covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform. Dario’s next-generation, AI-powered, digital therapeutic solutions support more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions; intuitive, clinically proven digital tools; high-quality software; and coaching to help individuals improve health and sustain meaningful outcomes. Dario’s unique user-centric approach to product design and engagement creates an unparalleled experience that is highly rated by users and delivers sustainable results. The company’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology, and uses a performance-based approach to improve its users’ health. Dario makes the right thing to do the easy thing to do. For more information about the company, please visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
